Historical record - last NADAC publication: 7/1/2016
Product Information
VELCADE 3.5 MG VIAL is a brand product labeled by Takeda Pharmaceuticals America, Inc., priced at $1508.2109 per EA under NDC 63020004901. Its NADAC has been published 139 times since Nov 19, 2014.
The High Outlier badge above means this manufacturer's average price in the bortezomib market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
3.5 mg/1
Manufacturer
Takeda Pharmaceuticals America, Inc.NDC
63020004901
Classification
Brand
Dosage Form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Route
INTRAVENOUS; SUBCUTANEOUS
Last Updated
7/1/2016
Active Ingredients
BORTEZOMIBApproval Type
New Drug (NDA)
FDA Application
NDA021602On Market Since
5/13/2003
Pharmacological Classes
Price Statistics
The NADAC for VELCADE 3.5 MG VIAL has been published 139 times since Nov 19, 2014, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $1508.2109 per EA |
|---|---|
| All-time high | $1516.6740 (Jul 6, 2016) |
| All-time low | $1491.2640 (Nov 19, 2014) |
| Median price | $1508.2109 |
| Average price | $1510.0965 |
| Largest weekly change | +1.1% (Jan 14, 2015) |
| Weeks tracked | 139 |
| Tracking since | Nov 19, 2014 |
Generic Alternatives
The matcher finds 2 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 2 manufacturers (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 97% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of VELCADE 3.5 MG VIAL?
The current National Average Drug Acquisition Cost (NADAC) for VELCADE 3.5 MG VIAL, manufactured by Takeda Pharmaceuticals America, Inc., is $1508.2109 per EA (NDC 63020004901), effective Jul 12, 2017.
How has the price of VELCADE 3.5 MG VIAL changed over time?
Over the history we have for it, the NADAC for VELCADE 3.5 MG VIAL has held within roughly two percent of its current level. It has been tracked across 139 weekly CMS publications since Nov 19, 2014.
What are the highest and lowest recorded NADAC prices for VELCADE 3.5 MG VIAL?
Since Nov 19, 2014, the NADAC for VELCADE 3.5 MG VIAL has ranged from a low of $1491.2640 (Nov 19, 2014) to a high of $1516.6740 (Jul 6, 2016), with a median of $1508.2109 per EA.
Are there cheaper alternatives to VELCADE 3.5 MG VIAL?
Yes. 2 NADAC-published products share the same active ingredient, strength, and dosage form. The lowest-priced option, BORTEZOMIB 3.5 MG VIAL, is $43.3460 per EA — about 97% below VELCADE 3.5 MG VIAL.
Who manufactures VELCADE 3.5 MG VIAL?
VELCADE 3.5 MG VIAL (NDC 63020004901) is labeled by Takeda Pharmaceuticals America, Inc., and CMS classifies it as a brand product.
Related Drugs
Same classification